We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

35 hedge funds and large institutions have $201M invested in Intra-Cellular Therapies Inc. in 2014 Q1 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
35
Holders Change
+35
Holders Change %
–
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
35
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$79.1M
2
BA
BlackRock Advisors
Delaware
+$19.2M
3
RG
Redmile Group
California
+$18.1M
4
Franklin Resources
Franklin Resources
California
+$15.2M
5
VAM
Visium Asset Management
New York
+$12.6M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$79.7M +$79.1M +4,383,412 New
BA
2
BlackRock Advisors
Delaware
$19.3M +$19.2M +1,061,147 New
RG
3
Redmile Group
California
$18.2M +$18.1M +1,001,060 New
Franklin Resources
4
Franklin Resources
California
$15.3M +$15.2M +840,300 New
VAM
5
Visium Asset Management
New York
$12.7M +$12.6M +700,479 New
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$7.27M +$7.22M +400,000 New
WSA
7
Wall Street Associates
California
$7.17M +$7.12M +394,357 New
BG
8
BlackRock Group
United Kingdom
$6.2M +$6.15M +340,933 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$6.14M +$6.1M +337,640 New
BC
10
Broadfin Capital
New York
$4.08M +$4.05M +224,234 New
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$3.54M +$3.51M +194,563 New
DM
12
Deerfield Management
New York
$3.12M +$3.09M +171,437 New
SCM
13
Sarissa Capital Management
Connecticut
$2.3M +$2.29M +126,695 New
Morgan Stanley
14
Morgan Stanley
New York
$2.23M +$2.21M +122,688 New
BlackRock
15
BlackRock
New York
$1.91M +$1.89M +104,800 New
SFM
16
Sphera Funds Management
Israel
$1.82M +$1.81M +100,000 New
RPAM
17
Rhenman & Partners Asset Management
Sweden
$1.79M +$1.77M +98,269 New
AC
18
Ascend Capital
California
$1.48M +$1.47M +81,231 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.01M +$1.01M +55,775 New
Deutsche Bank
20
Deutsche Bank
Germany
$908K +$903K +50,002 New
SONJCPFA
21
State of New Jersey Common Pension Fund A
New Jersey
$818K +$812K +45,000 New
CS
22
Credit Suisse
Switzerland
$660K +$655K +36,300 New
HCMT
23
Highland Capital Management (Texas)
Texas
$487K +$484K +26,809 New
Northern Trust
24
Northern Trust
Illinois
$375K +$372K +20,608 New
Tudor Investment Corp
25
Tudor Investment Corp
Connecticut
$364K +$361K +20,000 New
1
2

ITCI Hedge Fund Activity: Q1 2014 in Review

35 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2014, worth a combined $201M.

Buyers outnumbered sellers: 35 funds opened new ITCI positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $79.1M.

  • 35 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2014, up from 0 in Q4 2013.
  • Funds reported $201M of Intra-Cellular Therapies Inc. stock for Q1 2014.
  • 35 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2014 and 0 closed out, a net change of +35 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $79.1M added.

Based on aggregated 13F filings for Q1 2014.